TABLE 2:
P values from the post-hoc comparisons
| Comparison | P Value |
|---|---|
| No. of enhancing lesions | |
| Between SD and DD | .068* |
| Between SD and TD | .012 |
| Between DD and TD | .018 |
| Total enhancing area | |
| Between SD and DD | .043 |
| Between SD and TD | .008 |
| Between DD and TD | .012 |
| Mean CNR | |
| Between SD and DD | .063* |
| Between SD and TD | .011 |
| Between DD and TD | .028 |
Note—SD indicates a single dose (0.1 mmol/kg) of gadodiamide; DD, double dose (0.2 mmol/kg) of gadodiamide; and TD, triple dose (0.3 mmol/kg) of gadodiamide.
*
Not significant.